浙江迈同生物医药

Maitong Biomedical is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics. The company leverages a specialized platform for targeting protein-protein interactions (PPI), a field traditionally considered difficult for drug discovery. Its primary research efforts are directed toward oncology, specifically focusing on the regulation of apoptosis through targets such as MDM2 and BCL-2. Headquartered in the Binhai New Area of Shaoxing, Maitong was established by a team of industry veterans with extensive experience in global pharmaceutical R&D. The company integrates advanced medicinal chemistry with structural biology to create a pipeline of potent, selective drug candidates. Maitong aims to address significant unmet medical needs in cancer treatment through both internal development and strategic collaborations.